ABBV
Market read
ABBV accounts for 17.9% of the group's measured movement across 7.6 effective names. raw member direction is mixed; 7 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
AAMI, BXSL, ARES moved materially before ABBV. ABBV crossed its material path threshold at 14:05 ET, 165 minutes after the first measured mover. ARCC, BMY followed.
5 of 25 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.
Invalidation: The live read weakens if participation falls to 8 of 25 members or fewer.
Research brief
ABBV accounts for 17.9% of the group's measured movement across 7.6 effective names. raw member direction is mixed; 7 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Net revenues for Juvederm Collection decreased 3% for the three months ended March 31, 2026 primarily driven by decreased consumer demand, partially offset by favorable pricing due to customer loyalty program changes in the United States in the prior year and…”10-Q · May 8, 2026 ↗
“FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES Three months ended March 31, (in millions) 2026 2025 Cash flows provided by (used in): Operating activities $ 3,829 $ 1,635 Investing activities (574) (735) Financing activities 919 (1,258) Operating cash fl…”10-Q · May 8, 2026 ↗
“Other Non-Operating Expenses (Income) Three months ended September 30, Nine months ended September 30, (in millions) 2025 2024 2025 2024 Interest expense $ 739 $ 720 $ 2,179 $ 2,106 Interest income (72) (129) (207) (556) Interest expense, net $ 667 $ 591 $ 1,…”10-Q · Nov 4, 2025 ↗
“Other Non-Operating Expenses (Income) Three months ended September 30, Nine months ended September 30, (in millions) 2025 2024 2025 2024 Interest expense $ 739 $ 720 $ 2,179 $ 2,106 Interest income (72) (129) (207) (556) Interest expense, net $ 667 $ 591 $ 1,…”10-Q · Nov 4, 2025 ↗
Valuation discipline
Price/sales 7.4× · EV/sales 8.4×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for ABBV. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
Jodie has not yet found a suitable current-versus-prior filing comparison for ABBV. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“Epkinly • In May 2025, Genmab A/S (Genmab) announced positive topline results from the Phase 3 trial evaluating Epkinly plus rituximab and lenalidomide versus rituximab and lenalidomide alone in adult patients with relapsed or refractory (R/R) follicular lymp…”
Depended on by
“As of December 31, 2025 and 2024, the Company had recorded $ 10.9 million and $ 11.3 million, respectively, due from AbbVie for net reimbursement of costs incurred for activities performed under AbbVie Collaboration Agreement, which was included in other curr…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 27 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
ABBV is currently a Follower in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.